Senolytic therapy in MASH: a potential strategy for reducing fibrosis and preventing hepatocellular carcinoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F25%3A00085838" target="_blank" >RIV/00023001:_____/25:00085838 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Senolytic therapy in MASH: a potential strategy for reducing fibrosis and preventing hepatocellular carcinoma

Popis výsledku v původním jazyce

The incidence of metabolic dysfunction-associated steatohepatitis (MASH)increases in patients with metabolic diseases with aging, driven by cumulative metabolic stress,chronic inflammation, and progressive liver fibrosis. Despite extensive research, the limitedefficacy of current therapies, have prompted a search for novel therapeutic options. An example isthe therapeutic influence of cellular senescence, which contributes not only to the development ofmetabolic diseases like MASH, but also to the associated complications. Our goal was thereforeto test the mitochondria-targeted Tamoxifen (MitoTam), a potential anti-cancer agent withsenolytic activity, on reduction of MASH and related pathologies across the age groups.

Název v anglickém jazyce

Senolytic therapy in MASH: a potential strategy for reducing fibrosis and preventing hepatocellular carcinoma

Popis výsledku anglicky

The incidence of metabolic dysfunction-associated steatohepatitis (MASH)increases in patients with metabolic diseases with aging, driven by cumulative metabolic stress,chronic inflammation, and progressive liver fibrosis. Despite extensive research, the limitedefficacy of current therapies, have prompted a search for novel therapeutic options. An example isthe therapeutic influence of cellular senescence, which contributes not only to the development ofmetabolic diseases like MASH, but also to the associated complications. Our goal was thereforeto test the mitochondria-targeted Tamoxifen (MitoTam), a potential anti-cancer agent withsenolytic activity, on reduction of MASH and related pathologies across the age groups.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

<a href="/cs/project/LX22NPO5104" target="_blank" >LX22NPO5104: Národní institut pro výzkum metabolických a kardiovaskulárních onemocnění</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů